Findings

What do systematic reviews say?

2,908 questions · 3,101 findings · 509 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 571 · 18.4%GRADE not reported 358 · 11.5%Very low 723 · 23.3%Low 854 · 27.5%Moderate 489 · 15.8%High 106 · 3.4%

Sildenafil vs placebo

Change in oxygenation index ‐ After 24 hours of treatment · pulmonary hypertension in neonates

1 finding from 1 review

Sildenafil for pulmonary hypertension in neonates 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Low

Sildenafil vs placebo

All‐cause mortality · pulmonary hypertension in neonates

Sildenafil may leads to lower all‐cause mortality compared with placebo (low certainty).

1 finding from 1 review

Sildenafil for pulmonary hypertension in neonates 2017 · Cochrane Headline outcomes only
RR 0.2 [0.07, 0.56]
3 studies · 77 participants
Low

Sildenafil vs active control

All‐cause mortality · pulmonary hypertension in neonates

It is very uncertain whether sildenafil changes all‐cause mortality compared with active control (very low certainty).

1 finding from 1 review

Sildenafil for pulmonary hypertension in neonates 2017 · Cochrane Headline outcomes only
RR 0.55 [0.05, 5.75]
1 study · 65 participants
Very low

Sildenafil plus iNO vs placebo plus iNO

All‐cause mortality · pulmonary hypertension in neonates

Sildenafil plus iNO showed no clear difference in all‐cause mortality compared with placebo plus iNO (low certainty).

1 finding from 1 review

Sildenafil for pulmonary hypertension in neonates 2017 · Cochrane Headline outcomes only
RR 1.27 [0.26, 6.28]
1 study · 24 participants
Low

Sildenafil plus iNO vs placebo plus iNO

Length of hospital stay · pulmonary hypertension in neonates

1 finding from 1 review

Sildenafil for pulmonary hypertension in neonates 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Intervention not reported

Systolic BP ‐ Aliskiren 75 mg vs. placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1100 participants
Moderate

Intervention not reported

Systolic BP ‐ Aliskiren 150 mg vs. placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 3786 participants
Moderate

Intervention not reported

Systolic BP ‐ Aliskiren 300 mg vs. placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 3009 participants
Moderate

Intervention not reported

Systolic BP ‐ Aliskiren 600 mg vs. placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 393 participants
Low

Intervention not reported

Diastolic BP ‐ Aliskiren 75 mg vs placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1100 participants
Moderate

Intervention not reported

Diastolic BP ‐ Aliskiren 150 mg vs placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 3783 participants
Moderate

Intervention not reported

Diastolic BP ‐ Aliskiren 300 mg vs placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 3001 participants
Moderate

Intervention not reported

Diastolic BP ‐ Aliskiren 600 mg vs placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 393 participants
Low

Intervention not reported

Diarrhoea ‐ Aliskiren 600 mg vs placebo · primary hypertension

The intervention may leads to higher diarrhoea ‐ Aliskiren 600 mg vs placebo (low certainty).

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
RR 7 [2.48, 19.72]
2 studies · 592 participants
Low

Intervention not reported

Effect on systolic blood pressure (mean difference in systolic blood pressure) · adults with primary hypertension

The intervention showed no clear difference in effect on systolic blood pressure (mean difference in systolic blood… (moderate certainty).

1 finding from 1 review

Eplerenone for hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1437 participants
Moderate

Intervention not reported

Effect on diastolic blood pressure (mean difference in diastolic blood pressure) · adults with primary hypertension

The intervention showed no clear difference in effect on diastolic blood pressure (mean difference in diastolic… (moderate certainty).

1 finding from 1 review

Eplerenone for hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1437 participants
Moderate

Intervention not reported

Any adverse event · adults with primary hypertension

The intervention showed no clear difference in any adverse event (low certainty).

1 finding from 1 review

Eplerenone for hypertension 2017 · Cochrane Headline outcomes only
OR 1.07 [0.82, 1.41]
3 studies · 1105 participants
Low

Intervention not reported

Adverse event leading to withdrawal · adults with primary hypertension

The intervention showed no clear difference in adverse event leading to withdrawal (low certainty).

1 finding from 1 review

Eplerenone for hypertension 2017 · Cochrane Headline outcomes only
OR 1.1 [0.47, 2.55]
3 studies · 1105 participants
Low

Planned early birth vs expectant management

Maternal mortality or morbidity · pregnant women with hypertensive disorders from 34 weeks' gestation to term

Planned early delivery leads to lower composite maternal mortality and morbidity compared with expectant management (high certainty).

1 finding from 1 review

Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term 2017 · Cochrane Headline outcomes only
RR 0.69 [0.57, 0.83]
2 studies · 1459 participants
High

Planned early birth vs expectant management

Composite infant mortality and morbidity · pregnant women with hypertensive disorders from 34 weeks' gestation to term

1 finding from 1 review

Planned early delivery versus expectant management for hypertensive disorders from 34 weeks gestation to term 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1459 participants
GRADE not reported